Health Care · NASDAQ: REGN
Regeneron: how the business works
Regeneron invents and makes antibodies and other protein medicines, such as the eye injection EYLEA, and shares in Sanofi's Dupixent profits, with FY2025 revenue of $14.34 billion.
By Hardik Bhandare · Checked against filings: . Editorial policy. Corrections
Follow Regeneron
Email me when Regeneron's page is updated after earnings.
We'll send a confirmation email first. See our privacy policy.
Regeneron Pharmaceuticals, Inc. · Tarrytown, New York · Founded 1988
Updated for Q3 FY2026 · checked
- Revenue, FY2025
- $14.3B
- Net income, FY2025
- $4.5B
- Staff, Dec 31, 2025
- 15,410
- Candidates in clinical trials, Oct 2026
- About 50
- Founded
- 1988
The short version
Regeneron in 5 points
1 · What it sells
Regeneron sells antibody and other protein medicines; sales of its own medicines were $6.31 billion of its $14.34 billion FY2025 revenue, and US EYLEA sales were $2.75 billion.
2 · Who pays it
In FY2025, distributors buying Regeneron's own medicines paid 44% of revenue, Sanofi's profit share (mainly Dupixent) 41%, Bayer 9.9% and royalties and other 5.1%.
3 · What it keeps from $100
Of every $100 that came in during FY2025, Regeneron kept $28.1 as net income, which includes $10.6 of interest and investment income; operating income was $24.9 per $100 of revenue.
4 · Where the operating profit comes from
Regeneron reports one business segment and no profit by product; its largest revenue line, the Sanofi collaboration, was $5.88 billion, 41.0% of FY2025 revenue.
5 · The one thing to watch
US sales of EYLEA HD rose to $698.8 million in Q3 FY2026 from $430.6 million a year earlier, while older EYLEA fell to $399.7 million from $680.6 million.
Sources: From Regeneron's FY2025 10-K, Q3 FY2026 10-Q, 2026 proxy statement and earnings releases · checked
01Where the money goes · FY2025
Where does $100 of Regeneron's money go?
Regeneron · FY2025
Receipt for every $100
| Research and development | $36.5 |
|---|---|
| Selling, general and admin | $16.8 |
| Making medicines | $13.1 |
| Bought research, interest and other | $1.0 |
| Income tax | $4.5 |
| Kept as net income | $28.1 |
| Total | $100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly $100 because of rounding.
How this is worked out
Cityfort calculation from the FY2025 10-K. Of every $100 that came in during FY2025 (revenue of $14.34 billion plus $1.70 billion of other income, $16.04 billion in all): each line = line ÷ $16.04 billion × 100. Other income, mostly interest and gains on investments, was $10.6 of every $100.
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Each week: the next company due to report earnings, explained in 5 points.
No tips. Unsubscribe anytime.
We'll send a confirmation email. See our privacy policy.
02The business in one line
What does Regeneron do?
Distributors pay Regeneron for its own medicines and Sanofi pays it a share of Dupixent profits; research takes the most money, and what is left is profit.
- Sanofi collaboration revenue, mostly Dupixent profits, was 41.0% of FY2025 revenue. Sales of Regeneron's own medicines were $6.31 billion.
- Research took $5.85 billion in FY2025. US EYLEA sales fell from $4.77 billion in FY2024 to $2.75 billion after US exclusivity ended in May 2024.
03Who pays it
Who pays Regeneron?
Distributors buying its own medicines
44%
of revenue
Wholesalers and specialty distributors buy EYLEA HD, EYLEA, Libtayo and the smaller medicines. Net product sales were $6.31 billion in FY2025.
Sanofi (profit share, mainly Dupixent)
41%
of revenue
Sanofi pays Regeneron its share of profits on Dupixent and Kevzara, plus payments for supplying the medicine. $5.88 billion in FY2025.
Bayer (EYLEA outside the US)
9.9%
of revenue
Bayer sells EYLEA HD and EYLEA outside the US and shares the profits equally. $1.42 billion in FY2025.
Royalties and other
5.1%
of revenue
Includes royalties on Novartis's Ilaris and Regeneron's share of ARCALYST profits, plus other collaboration revenue. $727.4 million in FY2025.
- Distributors buying its own medicines44%
- Sanofi (profit share, mainly Dupixent)41%
- Bayer (EYLEA outside the US)9.9%
- Royalties and other5.1%
How spread out the customers are
Two unnamed distributors bought 50% and 27% of Regeneron's gross product sales in FY2025, 77% together. Separately, Sanofi collaboration revenue was 41.0% of total revenue.
Sources (1)
04How it makes money
How does Regeneron make money?
Regeneron earns from two engines: its own US sales and its share of profits on medicines partners sell.
In the partner engine, Sanofi books Dupixent sales, and Regeneron takes half of US profits. Research is the largest cost, $40.8 per $100 of FY2025 revenue (Cityfort calculation from the FY2025 10-K).
Operating income per $100 of revenue (Cityfort calculation from the FY2021 and FY2025 10-Ks)
$55.7$24.9
FY2021 to FY2025
- Regeneron scientists invent an antibody medicine
- Regeneron or a partner pays for trials
- Regeneron makes the medicine in its plants
- Regeneron sells it in the US, or a partner sells it
- Regeneron books sales or a profit share
- Cash pays for the next round of research
↺ Step 6 feeds back into step 1.
05Business segments · FY2025
Which businesses make up Regeneron?
Sanofi collaboration
41%Regeneron's share of Dupixent and Kevzara profits, plus supply payments. Regeneron reports one business segment, so no profit is given per line.
Revenue $5.9B ($5,884M)
EYLEA (US)
19.2%The older eye injection, now facing biosimilar copies in the US.
Revenue $2.7B ($2,748M)
EYLEA HD (US)
11.4%The higher-dose eye injection, approved by the FDA in August 2023.
Revenue $1.6B ($1,637M)
Libtayo (worldwide)
10.1%Cancer medicine; $944.7 million in the US and $507.5 million elsewhere.
Revenue $1.5B ($1,452M)
Bayer collaboration
9.9%Regeneron's share of EYLEA HD and EYLEA profits outside the US.
Revenue $1.4B ($1,422M)
Other medicines
3.3%Praluent, Evkeeza, Inmazeb and others (Cityfort calculation from the FY2025 10-K).
Revenue $472M
Royalties and other
5.1%Other revenue plus other collaboration revenue (Cityfort calculation from the FY2025 10-K).
Revenue $727M
How the mix changed
- Sanofi collaboration
- EYLEA (US)
- EYLEA HD (US)
- Libtayo (worldwide)
- Bayer collaboration
- Other medicines
- Royalties and other
Revenue by segment, FY2023 to FY2025.
US$
See the numbers
Sources (1)
06The numbers · Consolidated · US$
How has Regeneron done?
Revenue
$14.3BFY2025
Revenue fell from $16.07 billion in FY2021 to $12.17 billion in FY2022, then rose to $14.34 billion by FY2025.
US$
See the numbers
Net income
$4.5BFY2025
Net income was $8.08 billion in FY2021 and stayed between $3.95 billion and $4.50 billion from FY2022 to FY2025.
US$
See the numbers
Net income for every $100 of revenue
$31.4FY2025
Regeneron kept $31.4 of net income per $100 of revenue in FY2025, down from $50.2 in FY2021.
Net margin: $ of net income per $100 of revenue
See the numbers
Free cash flow
$4.1BFY2025
Free cash flow was $4.08 billion in FY2025, and stock-based pay, a cost paid in shares, was $993.7 million.
US$ · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA here = operating income plus depreciation and amortization (from the cash flow statement). Fiscal years are the company's own: Fiscal year ends Dec 31 (the calendar year). Net income is the share belonging to the company's owners.
Learn: Fiscal years that don't end in December: Nvidia's FY2027 explained · Stock-based compensation and dilution: pay that becomes shares
Sources (16)
- Form 10-K for FY2021
- Form 10-K for FY2022
- Form 10-K for FY2023
- Form 10-K for FY2024
- Form 10-K for FY2025
- Form 10-Q for Q1 FY2024
- Form 10-Q for Q2 FY2024
- Form 10-Q for Q3 FY2024
- Q4 FY2024 earnings release (8-K Ex. 99.1)
- Form 10-Q for Q1 FY2025
- Form 10-Q for Q2 FY2025
- Form 10-Q for Q3 FY2025
- Q4 FY2025 earnings release (8-K Ex. 99.1)
- Form 10-Q for Q1 FY2026
- Form 10-Q for Q2 FY2026
- Form 10-Q for Q3 FY2026
07Who runs it
Who runs Regeneron, and did they deliver?
Leonard S. Schleifer, M.D., Ph.D.
Co-Chair, President and Chief Executive Officer · since 1988
Founded Regeneron in 1988. Holds 95.0% of the 10-vote Class A shares.
George D. Yancopoulos, M.D., Ph.D.
Co-Chair, President and Chief Scientific Officer · since 1989
Joined in 1989 as founding scientist.
Christopher Fenimore
Executive Vice President, Finance and Chief Financial Officer · since 2024
Chief Financial Officer since February 2024.
Marion McCourt
Executive Vice President, Commercial · since 2021
Runs the sales business.
What they said, and what happened
3 too early to tell
Said on Jan 30, 2026
Regeneron said it expected 2026 GAAP research spending of $6.450 billion to $6.680 billion.
Too early to tellWhat happened
On Oct 30, 2026 it raised the range to $6.600 billion to $6.735 billion.
Said on Jan 30, 2026
Regeneron said it expected 2026 capital spending of $1.100 billion to $1.300 billion.
Too early to tellWhat happened
On Oct 30, 2026 it cut the range to $1.050 billion to $1.100 billion. Capital spending was $771.0 million in the first nine months.
Said on Oct 30, 2026
Leonard Schleifer said Regeneron expected an FDA decision on cemdisiran in generalized myasthenia gravis in November 2026.
Too early to tellWhat happened
No decision was reported in the filings used for this page.
08What could go wrong
What could go wrong for Regeneron?
- Competition
Biosimilar copies of EYLEA
EYLEA's US regulatory exclusivity ended in May 2024, and copies such as Amgen's Pavblu have been approved or launched. US EYLEA sales fell from $4.77 billion in FY2024 to $2.75 billion in FY2025.
Watch Combined US sales of EYLEA HD and EYLEA each quarter ($1.10 billion in Q3 FY2026, the Q3 FY2026 10-Q says).
- Concentration
Reliance on Dupixent and Sanofi
The 10-K says Regeneron depends heavily on Sanofi collaboration revenue, mainly Dupixent profits. It was 41.0% of FY2025 revenue.
Watch Dupixent global sales and Sanofi collaboration revenue in each release.
- Concentration
Two distributors buy most products
Two unnamed customers bought 50% and 27% of gross product sales in FY2025. They owed 87% of trade receivables at Dec 31, 2025.
Watch Customer shares in the 10-Q product sales note.
- Legal
Government and payer lawsuits
US Attorney's complaints filed in June 2020 and March 2024 allege Anti-Kickback and False Claims Act violations. Insurers such as UnitedHealthcare and Humana have filed related suits.
Watch Rulings on the alleged violations, as reported in the legal note of each 10-Q.
- Execution
Manufacturing problems
A temporary manufacturing interruption raised costs in the first half of 2026. It took about 3 points off the nine-month 2026 GAAP gross margin on product sales, which was 79%.
Watch Gross margin on product sales against the company's "about 80%" 2026 guidance.
- Execution
Research may not pay off
Research spending was $5.85 billion in FY2025, $40.8 of every $100 of revenue (Cityfort calculation from the FY2025 10-K). Trials can fail or be delayed.
Watch The FDA's February 2027 target action date for Ordspono, stated in the Q3 FY2026 release (Oct 30, 2026).
- Governance
Founder voting control
Class A shares have 10 votes each. Directors and officers held 17.6% of the votes on Sep 30, 2026, against 5.2% of the common stock.
Watch Class A share count and voting share in each 10-Q.
09Supporters vs. critics
What do supporters and critics point to?
What supporters point to
- Sanofi collaboration revenue, mostly Regeneron's share of Dupixent profits, was $2.72 billion in Q3 FY2026, up from $1.62 billion a year earlier.
- Revenue was $5.12 billion in Q3 FY2026, up from $3.75 billion in Q3 FY2025.
- Cash and marketable securities were $18.86 billion on Sep 30, 2026, against $1.99 billion of notes.
- Libtayo sales were $550.0 million in Q3 FY2026, up from $365.2 million a year earlier.
- About 50 candidates were in clinical trials in Oct 2026, and the FDA approved Pasatru for a rare bone disease in August 2026.
What critics point to
- US EYLEA sales fell from $4.77 billion in FY2024 to $2.75 billion in FY2025, after US regulatory exclusivity ended in May 2024 and copies such as Amgen's Pavblu were approved.
- Net income per $100 of revenue was $31.4 in FY2025, down from $50.2 in FY2021.
- Two unnamed distributors bought 77% of gross product sales in FY2025, and the Sanofi collaboration was 41.0% of revenue.
- US Attorney's complaints filed in June 2020 and March 2024 allege Anti-Kickback and False Claims Act violations, the Q3 FY2026 10-Q says.
- Class A shares carry 10 votes each: directors and officers held 17.6% of the votes on Sep 30, 2026, against 5.2% of the common stock.
10What to watch next
What should you watch next at Regeneron?
Next event
Q4 FY2026 results
Date not announced yet.
EYLEA HD and EYLEA in the US
Combined US sales were $1.10 billion in Q3 FY2026, the Q3 FY2026 10-Q says. EYLEA HD rose to $698.8 million while older EYLEA fell to $399.7 million.
$1.0 billion from Sanofi
Regeneron said on Oct 30, 2026 that the $1.0 billion upfront payment under its Oct 1, 2026 Sanofi amendment will be recorded as collaboration revenue in Q4 FY2026.
FDA decisions
Leonard Schleifer said on Oct 30, 2026 that Regeneron expected an FDA decision on cemdisiran in generalized myasthenia gravis in November 2026. The FDA's target date for Ordspono in a type of lymphoma is February 2027.
11Key facts
Key facts about Regeneron
- What does Regeneron do?
- Regeneron Pharmaceuticals invents antibody and other protein medicines, given as injections, and makes them in plants in Rensselaer, New York and Limerick, Ireland. Its medicines include EYLEA HD, EYLEA, Libtayo and, with Sanofi, Dupixent.
- How does Regeneron make money?
- Of Regeneron's $14.34 billion of FY2025 revenue, $6.31 billion came from selling its own medicines and $7.33 billion was collaboration revenue, mostly its share of Dupixent profits from Sanofi.
- Who are Regeneron's customers?
- Wholesalers and specialty distributors buy Regeneron's own medicines; two unnamed distributors bought 50% and 27% of its gross product sales in FY2025. Sanofi collaboration revenue was 41.0% of Regeneron's FY2025 revenue.
- How big is Regeneron?
- Regeneron had revenue of $14.34 billion and net income of $4.50 billion in FY2025, and 15,410 full-time employees on Dec 31, 2025.
- Who owns Regeneron?
- Regeneron's directors and officers held 5.2% of its common stock and 17.6% of the votes on Sep 30, 2026, the Q3 FY2026 10-Q says. Co-founder Leonard Schleifer held 95.0% of Regeneron's 10-vote Class A shares on Apr 14, 2026.
- How does Regeneron earn from Dupixent?
- Dupixent, an injection for eczema and asthma, is sold by Sanofi, which recorded $17.81 billion of Dupixent sales in FY2025. Regeneron shares US Dupixent profits equally with Sanofi and books its share as collaboration revenue.
- What happened to Regeneron's EYLEA sales?
- Regeneron's US sales of EYLEA fell from $4.77 billion in FY2024 to $2.75 billion in FY2025, after EYLEA's US regulatory exclusivity ended in May 2024 and biosimilar copies were approved. US sales of the higher-dose EYLEA HD were $1.64 billion in FY2025.
- Does Regeneron pay a dividend?
- Regeneron declared its first dividend in February 2025 and declared quarterly dividends of $0.88 a share in 2025. Regeneron also spent $3.44 billion buying back its own shares in FY2025.
- How much cash and debt does Regeneron have?
- On Sep 30, 2026 Regeneron had $18.86 billion of cash and marketable securities and $1.99 billion of notes outstanding.
Terms on this page
- Capital expenditures (capex)
- Debt-to-equity
- Earnings per share (EPS)
- EBITDA
- Free cash flow
- Net debt
- Net margin
- Revenue vs net income
- Stock buyback
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
12What it sells
12What it sells
What does Regeneron sell?
EYLEA HD and EYLEA
Eye injections for wet age-related macular degeneration and diabetic eye disease. Regeneron sells them in the US; Bayer sells them elsewhere.
Dupixent (with Sanofi)
Injection for atopic dermatitis (eczema) and asthma. Sanofi records the sales, $17.81 billion in FY2025, and Regeneron earns a share of the profits.
Libtayo
Cancer medicine, including for a type of skin cancer (cutaneous squamous cell carcinoma). Regeneron sold $1.45 billion of it worldwide in FY2025.
Smaller medicines
Praluent, Evkeeza, Inmazeb and others. Together they were $472.2 million of FY2025 sales (Cityfort calculation from the FY2025 10-K).
What it does
- Does: Discovers and develops its own medicines; about 50 were in clinical trials in Oct 2026
- Does: Makes antibodies in plants in Rensselaer, New York and Limerick, Ireland
- Does: Sells EYLEA HD, EYLEA and Libtayo in the US itself
What it does not do
- Does not: Book Dupixent sales as its own revenue; Sanofi records them
- Does not: Sell EYLEA outside the US; Bayer does
- Does not: Sell to patients directly; distributors buy its medicines
13How the money flows
13How the money flows · FY2025
How does money flow through Regeneron?
Money in
- Sales of its own medicines$6.3B
- Collaboration revenue (Sanofi, Bayer, others)$7.3B
- Other revenue (including royalties)$703M
- Other income (interest and investment gains)$1.7B
The company
Regeneron
$16.0B came in
Money out
- Research and development$5.9B
- Selling, general and admin$2.7B
- Making medicines, its own and for partners$2.1B
- Bought research, interest and other items$158M
- Income tax$726M
- Net income$4.5B
- Regeneron took in $14.34 billion of revenue in FY2025, and its investments added $1.70 billion of other income.
- Collaboration revenue, mostly Regeneron's share of Dupixent profits from Sanofi, was $7.33 billion, more than its $6.31 billion of own product sales.
- Research took $5.85 billion, and selling and admin took $2.70 billion.
- Making medicines, its own and those it supplies to partners, cost $2.10 billion.
- After $725.8 million of income tax, $4.50 billion was left as net income.
Sources (1)
14What it needs to run
14What it needs to run
What does Regeneron need to run?
Antibody plants
About 100,000 liters of cell-culture capacity in Rensselaer, New York and about 120,000 liters in Limerick, Ireland. A new Rensselaer fill-and-finish plant was not yet approved for commercial use.
Scientists and staff
15,410 full-time employees at Dec 31, 2025: 11,961 in the US, 2,149 in Ireland and 1,300 elsewhere.
Partners
Sanofi pays for most Dupixent development and sells it; Bayer sells EYLEA outside the US. Both share profits with Regeneron.
Suppliers
Some materials and services come from a single outside supplier, the 10-K says.
Sources (1)
15Competitors and what protects it
15Competitors and what protects it
Who does Regeneron compete with?
Genentech/Roche
Sells Vabysmo and Susvimo, eye medicines that compete with EYLEA HD and EYLEA, and Lucentis with Novartis.
Novartis
Sells Beovu, another eye injection of the same type (a VEGF inhibitor).
Amgen
NASDAQ: AMGN
Its Pavblu, a biosimilar copy of EYLEA, is approved or launched in the US, the 10-Q says.
Biocon
Its Yesafili, a biosimilar copy of EYLEA, is approved or launched in the US, the 10-Q says.
What protects the business
Each strength is scored 1 (weak) to 5 (strong) for the business, with the reason. It is not a rating of the share.
- Share of Dupixent profits4 of 5
Dupixent global sales, recorded by Sanofi, were $17.81 billion in FY2025. Regeneron shares US profits equally with Sanofi.
- Patents3 of 5
A US patent term extension covers Dupixent to Mar 28, 2031. EYLEA's US regulatory exclusivity ended in May 2024.
- Own manufacturing3 of 5
About 220,000 liters of FDA-approved cell-culture capacity in New York and Ireland (Cityfort calculation from the FY2025 10-K).
- Research spending4 of 5
Research and development was $5.85 billion in FY2025, and about 50 product candidates were in clinical trials in Oct 2026.
Weak spot
EYLEA copies
US EYLEA sales fell from $4.77 billion in FY2024 to $2.75 billion in FY2025, a 42.4% fall (Cityfort calculation from the FY2025 10-K).
16Where growth could come from
16Where growth could come from
Where could Regeneron's growth come from?
On Oct 30, 2026, Regeneron said it expects 2026 GAAP research spending of $6.600 billion to $6.735 billion, capital spending of $1.050 billion to $1.100 billion and a GAAP gross margin on product sales of about 80%. It gives no revenue or earnings guidance.
Dupixent
Working$6.5B Q3 FY2026 global sales, +35%
Sanofi records Dupixent sales. Regeneron's Sanofi collaboration revenue was $2.72 billion in Q3 FY2026, up from $1.62 billion a year earlier.
Status: Working, on track against what the company said.
Switching patients to EYLEA HD
MixedEYLEA HD US: $698.8M in Q3 FY2026
EYLEA HD US sales rose from $430.6 million a year earlier. Older EYLEA US sales fell from $680.6 million to $399.7 million.
Status: Mixed, partly on track.
Libtayo
Working$550.0M Q3 FY2026, up from $365.2M
Japan approved Libtayo for skin cancer after surgery (adjuvant CSCC) in August 2026.
Status: Working, on track against what the company said.
New Sanofi antibodies
New$1.0B upfront, up to $7.0B milestones
An Oct 1, 2026 amendment adds four long-acting antibodies to the Sanofi deal, with profits and costs shared equally. Regeneron said on Oct 30, 2026 that the $1.0 billion upfront will be booked as revenue in Q4 FY2026.
Status: New, recently announced.
Pipeline
EarlyAbout 50 candidates in clinical trials
The FDA approved Pasatru for a rare bone disease (FOP) in August 2026. The FDA set February 2027 as its target date for Ordspono in a type of lymphoma.
Status: Early, too early to judge.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
17The company's own measures (non-GAAP)
17The company's own measures · FY2024, FY2025 and Q3 FY2026
What do Regeneron's own measures show?
Official (GAAP): Diluted EPS, FY2025
$41.48
Company's own measure: Non-GAAP diluted EPS, FY2025
$44.31
Regeneron's adjusted figures leave out items such as stock-based payPay given as shares instead of cash, which spreads ownership more thinly. Learn more, amortization of intangible assets, litigation settlements and their tax effects.
Official (GAAP): Net income, FY2025
$4.5B
Company's own measure: Non-GAAP net income, FY2025
$4.9B
Same exclusions as non-GAAPThe company's own "adjusted" numbers, not the official (GAAP) ones. Always read them next to the official figure. Learn more EPS.
Official (GAAP): Diluted EPS, FY2024
$38.34
Company's own measure: Non-GAAP diluted EPS, FY2024
$45.62
Same type of exclusions.
Official (GAAP): Diluted EPS, Q3 FY2026
$18.45
Company's own measure: Non-GAAP diluted EPS, Q3 FY2026
$20.07
Same type of exclusions; the Q3 FY2026 release also leaves out temporary manufacturing interruption costs.
Official (GAAP): Cash from operations, first nine months of 2026
$3.7B
Company's own measure: Free cash flow, first nine months of 2026
$2.9B
Regeneron's own measure: cash from operations minus $771.0 million of capital spending.
These are the company's own measures, defined by the company. They are not comparable across companies, and they are not added together. Each sits beside the nearest official (GAAP) figure.
Learn: Non-GAAP measures: what a company's "adjusted" numbers leave out · Stock-based compensation and dilution: pay that becomes shares
18Financial strength and debt
18Financial strength · Sep 30, 2026
How much debt does Regeneron have?
- Total debt$2.0B
- Cash and investments$18.9B
- Net cash (cash minus debt)$16.9B
- Net worth (shareholders' money)$33.5B
- Debt to equity
- 0.06×
- $ of debt for every $1 of shareholders' money
- Net cash of $16.87 billion = cash and marketable securities minus long-term debt (Cityfort calculation from the Q3 FY2026 earnings release).
- The debt is two bond issues: 1.750% notes due 2030 and 2.800% notes due 2050. A $720.0 million finance lease is shown separately and not counted as debt here.
- A $750.0 million revolving credit line had nothing drawn on Sep 30, 2026.
19Who owns it
19Who owns it · ownership as of Apr 14, 2026
Who owns Regeneron?
- Officers and directors (as a group), shares
- 5.2%
- Officers and directors (as a group), votes
- 17.6%
Shares vs votes by class
Regeneron has more than one class of shares, and the classes carry different votes. The share of votes a class holds can differ a lot from its share of the shares.
- Common stock: share of all votes84.8%
- Class A stock: share of all votes15.2%
Each class's part of all votes = its shares outstanding × votes per share ÷ the total for all classes.
Share classes
Holders of 5% or more
From the company's proxy statement (DEF 14A), later Schedule 13G filings and the share counts on its latest annual or quarterly report. Each holder row shows the date of its own filing.
Learn: Dual-class shares: when votes and ownership don't match · How to read a proxy statement (DEF 14A): Nvidia's 2026 proxy · Form 4 insider filings: who files, the codes and the footnotes
20What it does with profit
20What it does with profit
What does Regeneron do with its profit?
Dividend per share
$3.52FY2025
Dividend paid for each share, by financial year.
$ per share
See the numbers
Buyback · Dec 31, 2023
Spent $2.24 billion buying back its own shares in 2023.
$2.2B
Buyback · Dec 31, 2024
Spent $2.60 billion on buybacks in 2024.
$2.6B
Buyback · Dec 31, 2025
Spent $3.44 billion on buybacks in 2025.
$3.4B
Buyback · Sep 30, 2026
Bought back about $2.3 billion of shares in the first nine months of 2026; $2.2 billion of authorization remained on Sep 30, 2026.
$2.3B
21Governance signals
21Governance signals
What do Regeneron's governance filings show?
- Auditor
- PricewaterhouseCoopers LLP
- Auditor changes
- None in the period covered
- Audit qualifications
- None reported
- Related-party dealings
- The 2026 proxy says related person transactions above $10,000 a year go through a written Audit Committee review policy.
- Credit rating
- Not checked for this page
Flags to know about
other
Two share classes
Class A shares have 10 votes each and carried 15.2% of all votes on Sep 30, 2026. Leonard Schleifer held 95.0% of them on Apr 14, 2026.
regulatory · Sep 30, 2026
US government lawsuits
A June 2020 US Attorney's civil complaint alleges Anti-Kickback Statute violations tied to Regeneron's support of patient-assistance charities. A March 2024 complaint concerns alleged inflated EYLEA reimbursement rates.
other
Board
11 of 13 directors are independent under Nasdaq rules. Christine A. Poon has been Lead Independent Director since 2023.
22How it got here
22How it got here
How did Regeneron get here?
1988
Milestone
Founded
Leonard Schleifer founded Regeneron; George Yancopoulos joined in 1989 as founding scientist.
2023
Business-model change
EYLEA HD approved
The FDA approved the higher-dose EYLEA HD in August 2023.
2024
Crisis
EYLEA copies arrive
EYLEA's US regulatory exclusivity ended in May 2024, opening the way for biosimilar copies.
2025
Milestone
First dividend
The board declared Regeneron's first quarterly dividend, $0.88 a share, in February 2025.
2025
Milestone
Collaboration revenue passes product sales
Collaboration revenue from Sanofi, Bayer and others was $7.33 billion in FY2025, above Regeneron's $6.31 billion of own product sales.
2026
Milestone
Sanofi development balance repaid
The balance Regeneron owed Sanofi for development costs was fully repaid by the end of Q2 FY2026.
2026
Business-model change
New Sanofi antibody deal
On Oct 1, 2026 the two companies added four long-acting antibodies to their partnership, with a $1.0 billion upfront payment to Regeneron.
23Sources and changes
Where every number on this page comes from
Sources (20 documents)
- S1Form 10-Q for Q3 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Oct 30, 2026
- S2Form 10-Q for Q2 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Jul 30, 2026
- S3Form 10-Q for Q1 FY2026 · SEC EDGAR · Tier 1: company or exchange filing · Apr 29, 2026
- S4Form 10-K for FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Feb 4, 2026
- S5Form 10-Q for Q3 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Oct 28, 2025
- S6Form 10-Q for Q2 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Aug 1, 2025
- S7Form 10-Q for Q1 FY2025 · SEC EDGAR · Tier 1: company or exchange filing · Apr 29, 2025
- S8Form 10-K for FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Feb 5, 2025
- S9Form 10-Q for Q3 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Oct 31, 2024
- S10Form 10-Q for Q2 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · Aug 1, 2024
- S11Form 10-Q for Q1 FY2024 · SEC EDGAR · Tier 1: company or exchange filing · May 2, 2024
- S12Form 10-K for FY2023 · SEC EDGAR · Tier 1: company or exchange filing · Feb 5, 2024
- S13Form 10-K for FY2022 · SEC EDGAR · Tier 1: company or exchange filing · Feb 6, 2023
- S14Form 10-K for FY2021 · SEC EDGAR · Tier 1: company or exchange filing · Feb 7, 2022
- S152026 Proxy Statement (DEF 14A) · SEC EDGAR · Tier 1: company or exchange filing · Apr 24, 2026
- S16Q3 FY2026 earnings release (8-K Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Oct 30, 2026
- S18Q1 FY2026 earnings release (8-K Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Apr 29, 2026
- S19Q4 FY2025 earnings release (8-K Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Jan 30, 2026
- S20Q4 FY2024 earnings release (8-K Ex. 99.1) · SEC EDGAR · Tier 1: company or exchange filing · Feb 4, 2025
- S218-K filed Oct 6, 2026 (Sanofi agreement dated Oct 1, 2026) · SEC EDGAR · Tier 1: company or exchange filing · Oct 6, 2026
Changes to this page (v1 · Nov 20, 2026)
- v1 · Nov 20, 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a registered investment adviser or broker-dealer and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a registered investment adviser or other qualified professional.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Cityfort is not paid by any company it covers. Content is not an offer or solicitation to buy or sell any security, including in any initial public offering.
Read the positions policyRead the full disclaimerHide the full disclaimer
Cityfort publishes general educational content that explains how listed companies work. Cityfort is not registered with the US Securities and Exchange Commission or any state securities regulator as an investment adviser, and is not a broker-dealer or a member of FINRA. Cityfort does not provide investment, tax or legal advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security. Nothing on the site is tailored to any person's circumstances.
All information is taken from publicly available sources, mainly company filings with the SEC, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management, including forward-looking statements and guidance, are reported as the company's statements, with their date and source; they are not our forecasts. Adjusted (non-GAAP) figures are the company's own measures and are shown next to the official (GAAP) figures.